Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Sema4 Holdings Corp WT (NQ: SMFRW )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sema4 Holdings Corp WT

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
From GeneDx Holdings Corp.
Via GlobeNewswire
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation 
From Sema4
Via GlobeNewswire
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
Data underscores the value of mitochondrial DNA testing and the opportunity to improve health outcomes for critically ill newborns with early medical intervention 
From Sema4
Via GlobeNewswire
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
From Sema4
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bed Bath & Beyond, Sema4, Medtronic, and Palantir and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
From Sema4
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
Guideline adoption can help end the diagnostic odyssey experienced by many families 
From Sema4
Via GlobeNewswire
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
From Sema4
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
Exome and genome tests report 30% fewer inconclusive results and a higher diagnostic yield compared to multi-gene panel tests; research to be presented at American Society of Human Genetics Annual... 
From Sema4
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TuSimple, Kohl’s, Bed Bath & Beyond, and Sema4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
From Sema4
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
The largest study of its kind in North America, GUARDIAN is expected to improve population health by identifying more than 250 preventable and treatable conditions, many of which are not covered today... 
From Sema4
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR NOTICE: Sema4 Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SMFR; SMFRW
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Investor Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Sema4 Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SMFR, SMFRW
From The Rosen Law Firm, P.A.
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sema4 Holdings Corp. (SMFR, SMFRW) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm
Via ACCESSWIRE
SEMA4 ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sema4 Holdings Corp. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
SEMA4 ALERT: Bragar Eagel & Squire, P.C. is Investigating Sema4 Holdings Corp. on Behalf of Sema4 Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
From Sema4
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.